246 related articles for article (PubMed ID: 35888771)
1. Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota.
Mori H; Svegliati Baroni G; Marzioni M; Di Nicola F; Santori P; Maroni L; Abenavoli L; Scarpellini E
Metabolites; 2022 Jul; 12(7):. PubMed ID: 35888771
[TBL] [Abstract][Full Text] [Related]
2. Fecal Microbiota Transplantation in NAFLD Treatment.
Abenavoli L; Maurizi V; Rinninella E; Tack J; Di Berardino A; Santori P; Rasetti C; Procopio AC; Boccuto L; Scarpellini E
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363516
[No Abstract] [Full Text] [Related]
3. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
[TBL] [Abstract][Full Text] [Related]
4. Bisphenol A induced hepatic steatosis by disturbing bile acid metabolism and FXR/TGR5 signaling pathways via remodeling the gut microbiota in CD-1 mice.
Hong T; Zou J; He Y; Zhang H; Liu H; Mai H; Yang J; Cao Z; Chen X; Yao J; Feng D
Sci Total Environ; 2023 Sep; 889():164307. PubMed ID: 37211107
[TBL] [Abstract][Full Text] [Related]
5. Diammonium Glycyrrhizinate Ameliorates Obesity Through Modulation of Gut Microbiota-Conjugated BAs-FXR Signaling.
Li Y; Hou H; Wang X; Dai X; Zhang W; Tang Q; Dong Y; Yan C; Wang B; Li Z; Cao H
Front Pharmacol; 2021; 12():796590. PubMed ID: 34992541
[TBL] [Abstract][Full Text] [Related]
6. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice.
Park MY; Kim SJ; Ko EK; Ahn SH; Seo H; Sung MK
J Appl Microbiol; 2016 Sep; 121(3):800-10. PubMed ID: 27111464
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
9. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.
Wang S; Sheng F; Zou L; Xiao J; Li P
J Adv Res; 2021 Dec; 34():109-122. PubMed ID: 35024184
[TBL] [Abstract][Full Text] [Related]
10. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside Rh4 Improves Hepatic Lipid Metabolism and Inflammation in a Model of NAFLD by Targeting the Gut Liver Axis and Modulating the FXR Signaling Pathway.
Yang S; Duan Z; Zhang S; Fan C; Zhu C; Fu R; Ma X; Fan D
Foods; 2023 Jun; 12(13):. PubMed ID: 37444230
[TBL] [Abstract][Full Text] [Related]
12. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters.
Sun L; Pang Y; Wang X; Wu Q; Liu H; Liu B; Liu G; Ye M; Kong W; Jiang C
Acta Pharm Sin B; 2019 Jul; 9(4):702-710. PubMed ID: 31384531
[TBL] [Abstract][Full Text] [Related]
13. FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by
Ye X; Huang D; Dong Z; Wang X; Ning M; Xia J; Shen S; Wu S; Shi Y; Wang J; Wan X
Microbiol Spectr; 2022 Oct; 10(5):e0051822. PubMed ID: 36036629
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal interactions between bile acids and gut microbiota in human liver diseases.
Ikegami T; Honda A
Hepatol Res; 2018 Jan; 48(1):15-27. PubMed ID: 29150974
[TBL] [Abstract][Full Text] [Related]
15. Discovery of farnesoid X receptor and its role in bile acid metabolism.
Chiang JYL; Ferrell JM
Mol Cell Endocrinol; 2022 May; 548():111618. PubMed ID: 35283218
[TBL] [Abstract][Full Text] [Related]
16. Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice.
Yang M; Wang H; Bukhari I; Zhao Y; Huang H; Yu Y; Sun X; Mi Y; Mei L; Zheng P
Front Nutr; 2023; 10():1121203. PubMed ID: 37545590
[TBL] [Abstract][Full Text] [Related]
17. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism.
Zhang L; Xie C; Nichols RG; Chan SH; Jiang C; Hao R; Smith PB; Cai J; Simons MN; Hatzakis E; Maranas CD; Gonzalez FJ; Patterson AD
mSystems; 2016; 1(5):. PubMed ID: 27822554
[TBL] [Abstract][Full Text] [Related]
19. The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease.
Ni Y; Lu M; Xu Y; Wang Q; Gu X; Li Y; Zhuang T; Xia C; Zhang T; Gou XJ; Zhou M
Front Microbiol; 2022; 13():908011. PubMed ID: 35832821
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
